Next date
None yet
Trials
13 active
27 in total · 26 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “The intervention will be administered orally (via syringe) with food twice daily.”In the company’s words, NCT06708299 on ClinicalTrials.gov
- Tested for
- Recurrent Pericarditis
- Main trialPhase 3
- “Multi-center, randomized, double-blind, placebo-controlled, phase-3 Trial. Patients with a history of recurrent pericarditis who are being treated with an IL-1 blocker for at least 12 months, scheduled to be discontinued, will be approached for potential trial participation. Double-blind treatment will be initiated 10 - 16 days prior to the last scheduled dose of the IL-1 blocker and continued for 24 weeks. The objective is to assess whether patients remain free of pericarditis recurrence while receiving CardiolRx.”In the company’s words, NCT06708299 on ClinicalTrials.gov
- Other names
- Pharmaceutically produced Cannabidiol · Cannabidiol
Other drugs for Recurrent Pericarditis
- KPL-387Kiniksa Pharmaceuticals International, plc · Phase 2/3
- GoflikiceptR-Pharm International, LLC · Phase 3
- VTX2735Zomagen Biosciences Ltd. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials27
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 21 Sep 2026 | CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) | |
| Phase 2/3Terminated | 30 Nov 2022 | Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors | |
| Phase 2Completed | 15 Jun 2024 | Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot) | |
| Phase 2Completed | 31 Jan 2025 | Impact of CardiolRx on Myocardial Recovery in Patients With Acute Myocarditis | |
| Phase 2Authorised | not given | Open-label pilot study to assess the efficacy and safety of Cannabidiol oral solution as an adjunctive treatment for children and young adults with rare disease-associated severe epilepsy | |
| Phase 2Not authorised | not given | Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE) | |
| Phase 2Not authorised | not given | Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE) | |
| Phase 2Authorised | not given | Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE) | |
| Phase 3Not authorised | not given | Randomized, double-blind, Placebo-controlled, 2x2 cross over study assessing the efficacy and safety of cANnabidiol oral solution for joint pain of adjuvant enDOcrine theRApy in patients with early breast cancer (PANDORA) | |
| Phase 3Authorised | not given | Randomized, double-blind, Placebo-controlled, 2x2 cross over study assessing the efficacy and safety of cANnabidiol oral solution for joint pain of adjuvant enDOcrine theRApy in patients with early breast cancer (PANDORA) | |
| Phase 2Ended | not given | Explorative, randomized, double-blind, placebo-controlled, 3-way cross-over study to assess the effects of oral cannabidiol 30 and 700 mg in healthy male subjects on CNS and cortical excitability using the NeuroCart test battery and TMS. | |
| Phase 2Authorised | not given | Efficacy and safety of cannabidiol for pain relief of patients with end-stage metastatic castration resistant prostate cancer - a randomised double-blinded placebo-controlled phase II trial (ProCan) | |
| Phase 2Authorised | not given | A phase 2a study on the anti-tumoral effect of cannabis oil (THC 10% / CBD 5%) in patients with untreatable advanced hepatocellular carcinoma - the CanHep study | |
| Phase 2Ended | not given | Cannabidiol as an Add-on Treatment to substance abuse in juvenile patients with PSYchosis: a double-blind randomized placebo-controlled study. | |
| Phase 2Ended | not given | A Pilot / Phase 2 Clinical Trial of GSL-01-001 Administered Orally for 12 Weeks Preceded by a 2 Week Screening Period in Patients Presenting with Symptoms Associated with Irritable Bowel Syndrome with code GSL-01-001 | |
| Phase 2Ended | not given | BOOSTCAMP - Boosting the endocannabinoid system before the treatment of anxiety symptoms | |
| Phase 2Halted | not given | CBD-ESPRIT - Enhancing recovery in early schizophrenia – a multi-center, two-arm, double-blind, randomized clinical trial investigating cannabidiol vs. placebo as an add-on to an individualized antipsychotic treatment | |
| Phase 2/3Ended | not given | Cannabidiol for treatment of non-affective psychosis and cannabis use | |
| Phase 2Ended | not given | Cannabidiol for reducing drinking in alcohol use disorder and modifying the effects of alcohol on the brain and the liver: a phase 2 clinical trial.- The CARAMEL Study | |
| Phase 2Authorised | not given | ICONICplus - Randomized, double-blind, placebo-controlled trial to investigate the Effects of Cannabidiol plus Naltrexone on Cue-Induced Alcohol Craving in Alcohol Dependence | |
| Phase 2Ended | not given | The CanISleepinMS Study: Effect of cannabidiol (CBD) on sleep quality in patients with multiple sclerosis, a series of 15 randomised, placebo-controlled N-of-1 trials | |
| Phase 2Authorised | not given | CBD-OH - Cannabidiol as an add-on treatment during inpatient alcohol cessation in patients with severe alcohol use disorder: a Phase II trial | |
| Phase 2Authorised | not given | The effect of CBD on sleep quality following late evening exercise | |
| Phase 2Authorised | not given | PANACEA : Effect of PrehAbilitation by NutritionAl supplementation with Cannabidiol on skeletal muscle mass and mitochondrial function in hEad and neck cAncer : a proof of concept controlled randomized trial | |
| Phase 3Authorised | not given | Cannabidiol (Epidyolex) for behavioural problems in patients with Tuberous Sclerosis Complex, Sanfilippo and Fragile X syndrome: an N-of-1 series | |
| Phase 2Authorised | not given | CBD-SIB - Efficacy of cannabidiol in the management of Self-Injurious Behavior in children and adolescents with severe neurodevelopmental disorders | |
| Phase 3Authorised | not given | AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026